Cargando…

Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018

Cardiometabolic multimorbidity (co-existence of ≥1 cardiometabolic diseases) is increasingly common, while its prevalence in the U.S. is unknown. We utilized data from 10 National Health and Nutrition Examination Survey (NHANES) two-year cycles in U.S. adults from 1999 to 2018. We reported the age-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Xunjie, Ma, Tianqi, Ouyang, Feiyun, Zhang, Guogang, Bai, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027860/
https://www.ncbi.nlm.nih.gov/pubmed/35457593
http://dx.doi.org/10.3390/ijerph19084726
_version_ 1784691472802512896
author Cheng, Xunjie
Ma, Tianqi
Ouyang, Feiyun
Zhang, Guogang
Bai, Yongping
author_facet Cheng, Xunjie
Ma, Tianqi
Ouyang, Feiyun
Zhang, Guogang
Bai, Yongping
author_sort Cheng, Xunjie
collection PubMed
description Cardiometabolic multimorbidity (co-existence of ≥1 cardiometabolic diseases) is increasingly common, while its prevalence in the U.S. is unknown. We utilized data from 10 National Health and Nutrition Examination Survey (NHANES) two-year cycles in U.S. adults from 1999 to 2018. We reported the age-standardized prevalence of cardiometabolic multimorbidity in 2017–2018 and analyzed their trends during 1999–2018 with joinpoint regression models. Stratified analyses were performed according to gender, age, and race/ethnicity. In 2017–2018, the prevalence of cardiometabolic multimorbidity was 14.4% in the U.S., and it was higher among male, older, and non-Hispanic Black people. The three most common patterns were hypertension and diabetes (7.5%); hypertension, diabetes, and CHD (2.2%); and hypertension and CHD (1.8%). During 1999–2018, the prevalence of cardiometabolic multimorbidity in U.S. adults increased significantly, with an averaged two-year cycle percentage change (AAPC) of 3.6 (95% CI: 2.1 to 5.3). The increasing trend was significant for both genders, most age groups except for 60–79 years, and non-Hispanic White people. For common patterns, the trend was increasing for hypertension and diabetes and hypertension, diabetes, and CHD, while it was decreasing for hypertension and CHD. Our findings provide evidence that cardiometabolic multimorbidity has risen as an austere issue of public health in the U.S.
format Online
Article
Text
id pubmed-9027860
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90278602022-04-23 Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018 Cheng, Xunjie Ma, Tianqi Ouyang, Feiyun Zhang, Guogang Bai, Yongping Int J Environ Res Public Health Article Cardiometabolic multimorbidity (co-existence of ≥1 cardiometabolic diseases) is increasingly common, while its prevalence in the U.S. is unknown. We utilized data from 10 National Health and Nutrition Examination Survey (NHANES) two-year cycles in U.S. adults from 1999 to 2018. We reported the age-standardized prevalence of cardiometabolic multimorbidity in 2017–2018 and analyzed their trends during 1999–2018 with joinpoint regression models. Stratified analyses were performed according to gender, age, and race/ethnicity. In 2017–2018, the prevalence of cardiometabolic multimorbidity was 14.4% in the U.S., and it was higher among male, older, and non-Hispanic Black people. The three most common patterns were hypertension and diabetes (7.5%); hypertension, diabetes, and CHD (2.2%); and hypertension and CHD (1.8%). During 1999–2018, the prevalence of cardiometabolic multimorbidity in U.S. adults increased significantly, with an averaged two-year cycle percentage change (AAPC) of 3.6 (95% CI: 2.1 to 5.3). The increasing trend was significant for both genders, most age groups except for 60–79 years, and non-Hispanic White people. For common patterns, the trend was increasing for hypertension and diabetes and hypertension, diabetes, and CHD, while it was decreasing for hypertension and CHD. Our findings provide evidence that cardiometabolic multimorbidity has risen as an austere issue of public health in the U.S. MDPI 2022-04-14 /pmc/articles/PMC9027860/ /pubmed/35457593 http://dx.doi.org/10.3390/ijerph19084726 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cheng, Xunjie
Ma, Tianqi
Ouyang, Feiyun
Zhang, Guogang
Bai, Yongping
Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018
title Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018
title_full Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018
title_fullStr Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018
title_full_unstemmed Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018
title_short Trends in the Prevalence of Cardiometabolic Multimorbidity in the United States, 1999–2018
title_sort trends in the prevalence of cardiometabolic multimorbidity in the united states, 1999–2018
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027860/
https://www.ncbi.nlm.nih.gov/pubmed/35457593
http://dx.doi.org/10.3390/ijerph19084726
work_keys_str_mv AT chengxunjie trendsintheprevalenceofcardiometabolicmultimorbidityintheunitedstates19992018
AT matianqi trendsintheprevalenceofcardiometabolicmultimorbidityintheunitedstates19992018
AT ouyangfeiyun trendsintheprevalenceofcardiometabolicmultimorbidityintheunitedstates19992018
AT zhangguogang trendsintheprevalenceofcardiometabolicmultimorbidityintheunitedstates19992018
AT baiyongping trendsintheprevalenceofcardiometabolicmultimorbidityintheunitedstates19992018